September 9, 2020 |By
AstraZeneca, in partnership with the University of Oxford, has halted its Phase 3 trials of a vaccine after a “standard review process” found a “potentially unexplained illness in one of the trials,” according to a statement obtained by the outlet on September 8.
The participant is located in the United Kingdom, STAT indicated.
AstraZeneca initiated its Phase 3 trial in the United States on August 31, according to an online news release.
— Rebecca Robbins (@RebeccaDRobbins) September 8, 2020
Although AstraZeneca did not disclose any details surrounding the participant or their adverse reaction, it indicated that it is “working to expedite the review of the single event to minimize any potential impact on the trial timeline,” according to STAT News.”